Journal Article
. 2017 Apr; 8(24):39356-39366.
doi: 10.18632/oncotarget.17000.

Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo

Bingyu Li 1 Lijun Xu 1 Fei Tao 1 Kun Xie 1 Zhiqiang Wu 1 You Li 1 Jie Li 1 Kaiming Chen 1 Chenyu Pi 1 Andrew Mendelsohn 2 James W Larrick 2 Hua Gu 1 Jianmin Fang 1 
Affiliations
  • PMID: 28454118
  •     36 References
  •     8 citations

Abstract

Therapeutic antibodies are effective for tumor immunotherapy and exhibit prominent clinical effects. All approved antibody therapeutics utilize IgG as the molecular format. Antibody-dependent cell-mediated cytotoxicity (ADCC) is a key mechanism for tumor cell killing by antibodies. For IgG antibodies, ADCC depends on FcγR-expressing cells, such as natural killer (NK) cells. However, in patients with a high tumor burden, antibody therapeutics may lose efficacy owing to exhaustion of FcγR-expressing effector cells as well as the inhibitory effects of certain FcγRs on effector cells. To achieve more potent effector functions, we engineered an anti-CD20 antibody to contain both IgG Fc and IgA Fc domains. These engineered antibodies interacted with both IgG and IgA Fc receptors (FcγR and FcαR) and recruited a broader range of effector cells, including monocytes, macrophages, neutrophils, and NK cells, thereby enhancing antibody-dependent cellular phagocytosis. Using transgenic mice expressing the FcαRI (CD89) in macrophages, we demonstrated that recombinant antibodies bearing the chimeric IgG and IgA Fc exhibited potent in vivo antitumor activity. Additionally, in a short-term peritoneal model using CD20-transfected LLC target cells, the in vivo cytotoxic activity of hybrid recombinant antibodies was mediated by macrophages with significant reduction in the absence of FcαRI. Our findings supported targeting of FcαRI on monocytes and macrophages for improved tumor immunotherapy.

Keywords: CD20; antibody-dependent cell-mediated cytotoxicity; antitumor activity; in vivo mouse model; relapse.

Clearance kinetics and fate of mouse IgA immune complexes prepared with monomeric or dimeric IgA.
A Rifai, M Mannik.
J Immunol, 1983 Apr 01; 130(4). PMID: 6833754
A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria.
A J Macpherson, D Gatto, +3 authors, R M Zinkernagel.
Science, 2000 Jun 24; 288(5474). PMID: 10864873
Highly Cited.
Mechanism of action of rituximab.
Thomas Cerny, Bettina Borisch, +2 authors, Andrea L Rose.
Anticancer Drugs, 2003 Apr 25; 13 Suppl 2. PMID: 12710585
Review.
Hepatic and kidney uptake of soluble monomeric and polymeric IgA aggregates.
J Sancho, E González, +2 authors, J Egido.
Immunology, 1984 May 01; 52(1). PMID: 6715019    Free PMC article.
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.
Michael Dechant, Thomas Beyer, +4 authors, Thomas Valerius.
J Immunol, 2007 Aug 22; 179(5). PMID: 17709508
The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis.
M van Egmond, A J Hanneke van Vuuren, J G van de Winkel.
Immunol Lett, 1999 Jul 09; 68(1). PMID: 10397160
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.
Junji Uchida, Yasuhito Hamaguchi, +4 authors, Thomas F Tedder.
J Exp Med, 2004 Jun 24; 199(12). PMID: 15210744    Free PMC article.
Highly Cited.
CD89: the human myeloid IgA Fc receptor.
H C Morton, P Brandtzaeg.
Arch Immunol Ther Exp (Warsz), 2001 Aug 02; 49(3). PMID: 11478396
Review.
IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions.
William Kelton, Nishant Mehta, +5 authors, George Georgiou.
Chem Biol, 2014 Dec 17; 21(12). PMID: 25500223
Bone Marrow-Derived Macrophages (BMM): Isolation and Applications.
Joachim Weischenfeldt, Bo Porse.
CSH Protoc, 2008 Jan 01; 2008. PMID: 21356739
Highly Cited.
IgA Fc receptors.
Renato C Monteiro, Jan G J Van De Winkel.
Annu Rev Immunol, 2003 Jan 14; 21. PMID: 12524384
Highly Cited. Review.
Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.
Saskia Meyer, Maaike Nederend, +10 authors, Jeanette H W Leusen.
MAbs, 2015 Oct 16; 8(1). PMID: 26466856    Free PMC article.
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
Matthias Peipp, Jeroen J Lammerts van Bueren, +9 authors, Thomas Valerius.
Blood, 2008 Jun 21; 112(6). PMID: 18566325
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.
Simone de Haij, J H Marco Jansen, +8 authors, Jeanette H W Leusen.
Cancer Res, 2010 Apr 01; 70(8). PMID: 20354182
Hybrid IgA2/IgG1 antibodies with tailor-made effector functions.
K R Chintalacharuvu, L U Vuong, +2 authors, S L Morrison.
Clin Immunol, 2001 Oct 03; 101(1). PMID: 11580223
Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients.
Annika Algars, Heikki Irjala, +5 authors, Sirpa Jalkanen.
Int J Cancer, 2011 Sep 29; 131(4). PMID: 21952788
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
R A Clynes, T L Towers, L G Presta, J V Ravetch.
Nat Med, 2000 Mar 31; 6(4). PMID: 10742152
Highly Cited.
IgA EGFR antibodies mediate tumour killing in vivo.
Peter Boross, Stefan Lohse, +13 authors, Jeanette H W Leusen.
EMBO Mol Med, 2013 Aug 07; 5(8). PMID: 23918228    Free PMC article.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Mitchell R Smith.
Oncogene, 2003 Oct 25; 22(47). PMID: 14576843
Highly Cited. Review.
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Gregory L Beatty, Elena G Chiorean, +10 authors, Robert H Vonderheide.
Science, 2011 Mar 26; 331(6024). PMID: 21436454    Free PMC article.
Highly Cited.
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Yasuhito Hamaguchi, Yan Xiu, +2 authors, Thomas F Tedder.
J Exp Med, 2006 Mar 08; 203(3). PMID: 16520392    Free PMC article.
Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages.
T Keler, P K Wallace, +4 authors, Y M Deo.
J Immunol, 2000 May 23; 164(11). PMID: 10820252
Antibody therapy of cancer.
Andrew M Scott, Jedd D Wolchok, Lloyd J Old.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437872
Highly Cited. Review.
Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity.
Huafei Li, Yun Sun, +10 authors, Wei Li.
Sci Rep, 2015 Oct 29; 5. PMID: 26508306    Free PMC article.
Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.
Stefan Lohse, Christina Brunke, +8 authors, Thomas Valerius.
J Biol Chem, 2012 Jun 09; 287(30). PMID: 22679018    Free PMC article.
M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
Marzia Leidi, Elisa Gotti, +7 authors, Josée Golay.
J Immunol, 2009 Mar 21; 182(7). PMID: 19299742
Highly Cited.
Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
S Mathas, A Rickers, +2 authors, M Y Mapara.
Cancer Res, 2001 Jan 13; 60(24). PMID: 11156427
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
M Jack Borrok, Nadia M Luheshi, +5 authors, Ping Tsui.
MAbs, 2015 May 15; 7(4). PMID: 25970007    Free PMC article.
A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Yvonne Guettinger, Karin Barbin, +8 authors, Bernhard Stockmeyer.
J Immunol, 2010 Jan 01; 184(3). PMID: 20042573
The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.
R P Junghans, C L Anderson.
Proc Natl Acad Sci U S A, 1996 May 28; 93(11). PMID: 8643606    Free PMC article.
Highly Cited.
Rituximab: mechanism of action.
George J Weiner.
Semin Hematol, 2010 Mar 31; 47(2). PMID: 20350658    Free PMC article.
Highly Cited. Review.
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.
Peter Boross, J H Marco Jansen, +8 authors, Jeanette H W Leusen.
Haematologica, 2011 Sep 02; 96(12). PMID: 21880632    Free PMC article.
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Evdoxia Hatjiharissi, Lian Xu, +13 authors, Steven P Treon.
Blood, 2007 May 04; 110(7). PMID: 17475906    Free PMC article.
Critical Role of Kupffer Cell CD89 Expression in Experimental IgA Nephropathy.
Lijun Xu, Bingyu Li, +5 authors, Jianmin Fang.
PLoS One, 2016 Jul 22; 11(7). PMID: 27437939    Free PMC article.
Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo.
Markus Biburger, Susanne Aschermann, +6 authors, Falk Nimmerjahn.
Immunity, 2011 Dec 16; 35(6). PMID: 22169040
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Michael J E Marshall, Richard J Stopforth, Mark S Cragg.
Front Immunol, 2017 Oct 20; 8. PMID: 29046676    Free PMC article.
Review.
CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.
Bingyu Li, Lijun Xu, +6 authors, Jianmin Fang.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296544    Free PMC article.
Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.
Arianne M Brandsma, Sina Bondza, +7 authors, Toine Ten Broeke.
Front Immunol, 2019 Apr 30; 10. PMID: 31031746    Free PMC article.
The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer.
Natasha Ustyanovska Avtenyuk, Nienke Visser, Edwin Bremer, Valerie R Wiersma.
Int J Mol Sci, 2020 Oct 28; 21(21). PMID: 33105656    Free PMC article.
Review.
Production, characterization, and in vivo half-life extension of polymeric IgA molecules in mice.
T Noelle Lombana, Sharmila Rajan, +16 authors, Christoph Spiess.
MAbs, 2019 May 28; 11(6). PMID: 31122132    Free PMC article.
Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents.
Geert van Tetering, Mitchell Evers, +2 authors, Jeanette Leusen.
Antibodies (Basel), 2020 Dec 19; 9(4). PMID: 33333967    Free PMC article.
Review.
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
Niels Heemskerk, Mandy Gruijs, +14 authors, Marjolein van Egmond.
J Clin Invest, 2021 Feb 10; 131(6). PMID: 33561014    Free PMC article.
Trogocytosis between Non-Immune Cells for Cell Clearance, and among Immune-Related Cells for Modulating Immune Responses and Autoimmunity.
Ko-Jen Li, Cheng-Han Wu, +5 authors, Chia-Li Yu.
Int J Mol Sci, 2021 Mar 07; 22(5). PMID: 33668117    Free PMC article.
Review.